AU2002305236A1 - Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent - Google Patents

Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent

Info

Publication number
AU2002305236A1
AU2002305236A1 AU2002305236A AU2002305236A AU2002305236A1 AU 2002305236 A1 AU2002305236 A1 AU 2002305236A1 AU 2002305236 A AU2002305236 A AU 2002305236A AU 2002305236 A AU2002305236 A AU 2002305236A AU 2002305236 A1 AU2002305236 A1 AU 2002305236A1
Authority
AU
Australia
Prior art keywords
kits
respiratory
formulations
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002305236A
Other versions
AU2002305236A8 (en
Inventor
Douglas Aguilar
Evan Katz
Yukui Li
Shoreh Miller
Jonathan W Nyce
Jonathan Pabalan
Anthony Sandrasagra
Syed Shahabuddin
Lei Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenesis Pharmaceuticals Inc
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Publication of AU2002305236A1 publication Critical patent/AU2002305236A1/en
Publication of AU2002305236A8 publication Critical patent/AU2002305236A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
AU2002305236A 2001-04-24 2002-04-23 Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent Abandoned AU2002305236A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28603601P 2001-04-24 2001-04-24
US60/286,036 2001-04-24
PCT/US2002/013143 WO2002085309A2 (en) 2001-04-24 2002-04-23 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent

Publications (2)

Publication Number Publication Date
AU2002305236A1 true AU2002305236A1 (en) 2002-11-05
AU2002305236A8 AU2002305236A8 (en) 2012-03-08

Family

ID=23096778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002305236A Abandoned AU2002305236A1 (en) 2001-04-24 2002-04-23 Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent

Country Status (2)

Country Link
AU (1) AU2002305236A1 (en)
WO (1) WO2002085309A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110003879A1 (en) * 2005-03-11 2011-01-06 Vincent Mark D Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
EP1758998B1 (en) 2004-01-30 2010-12-15 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
BRPI0512841A (en) * 2004-07-02 2008-01-08 Warner Lambert Co compositions and methods for treating pathological infections
DE602005025525D1 (en) 2004-11-17 2011-02-03 Amgen Inc COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
EP1859040A2 (en) 2005-02-25 2007-11-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
BRPI0610499A2 (en) 2005-04-12 2010-06-22 Intradigm Corp nucleic acid molecules, compositions and uses of said molecules
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US7713521B2 (en) 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions
RU2746478C2 (en) 2008-12-04 2021-04-14 КьюРНА, Инк. Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene
PT2396038E (en) * 2009-02-12 2016-02-19 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
EP2443237B1 (en) 2009-06-16 2017-02-22 CuRNA, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
PT2585596T (en) * 2010-06-23 2021-03-23 Curna Inc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2012015775A2 (en) 2010-07-28 2012-02-02 Dharmacon, Inc. Sirna targeting vegfa and methods for treatment in vivo
CN102370620B (en) * 2010-08-26 2013-03-20 同济大学附属上海市肺科医院 Pulmonic targeting immuno nano liposome and preparation method thereof
WO2015035231A1 (en) * 2013-09-05 2015-03-12 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
JP7153947B2 (en) * 2017-07-28 2022-10-17 ウニヴェルジテート ツー リューベック Antisense drug against canine ICAM-1 used for treatment of oral inflammation
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
JP2021526823A (en) * 2018-06-14 2021-10-11 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Compounds and methods for increasing STMN2 expression
US20230287499A1 (en) * 2020-06-03 2023-09-14 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
GB2603454A (en) * 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
CA3213775A1 (en) 2021-04-19 2022-10-27 Utsav SAXENA Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression

Also Published As

Publication number Publication date
AU2002305236A8 (en) 2012-03-08
WO2002085309A2 (en) 2002-10-31
WO2002085309A9 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
AU2002305236A1 (en) Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
AU2002303425A1 (en) Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
ZA200306234B (en) Phenethanolamine derivatives for treatment of respiratory diseases.
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
IL159067A0 (en) METHODS FOR PREPARATION AND USE OF 1alpha,24 (S) -DIHYDROXYVITAMIN D2
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
AU2001293891A1 (en) New combination for the treatment of asthma
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
EP1617810A4 (en) Methods for preparation and use of 1alpha,24(s)-dihydroxyvitamin d2
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
WO2001022956A3 (en) NOVEL COMBINATION OF LOTEPREDNOL AND β2-ADRENOCEPTOR AGONISTS
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
ZA200405173B (en) 2'-halo-3',5'-dialkoxyphen-1'yl-imino-2-imidazoline derivatives and the use thereof for the treatment of urinary incontinence.
AU2002347372A1 (en) Skin lightening agents, noel compounds, compositions and use
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
AU2002349788A1 (en) Fiber treatment agent composition
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
HK1070900A1 (en) Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
AU2003258177A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2002246307A1 (en) Polyherbal composition for the treatment of bronchial asthma and the process

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase